Rockwell Medical (NASDAQ:RMTI - Get Free Report) will be issuing its quarterly earnings data before the market opens on Monday, November 11th. Analysts expect the company to announce earnings of $0.01 per share for the quarter. Rockwell Medical has set its FY 2024 guidance at EPS.Investors that are interested in registering for the company's conference call can do so using this link.
Rockwell Medical (NASDAQ:RMTI - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.05. Rockwell Medical had a negative net margin of 5.06% and a negative return on equity of 6.96%. The firm had revenue of $25.83 million for the quarter, compared to analysts' expectations of $23.01 million. During the same quarter in the previous year, the firm posted ($0.18) earnings per share. On average, analysts expect Rockwell Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Rockwell Medical Price Performance
Shares of NASDAQ RMTI traded up $0.10 during mid-day trading on Monday, hitting $3.89. 438,119 shares of the stock traded hands, compared to its average volume of 298,857. The company has a market cap of $120.71 million, a PE ratio of -22.88 and a beta of 1.50. Rockwell Medical has a twelve month low of $1.16 and a twelve month high of $4.57. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.00 and a quick ratio of 1.60. The firm has a 50 day simple moving average of $3.59 and a two-hundred day simple moving average of $2.50.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and set a $9.00 price target on shares of Rockwell Medical in a report on Wednesday, September 11th.
Check Out Our Latest Report on Rockwell Medical
About Rockwell Medical
(
Get Free Report)
Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
Featured Stories
Before you consider Rockwell Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rockwell Medical wasn't on the list.
While Rockwell Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
